Abstract | PURPOSE: PATIENTS AND METHODS: Women with T1-2, N0-1 breast cancer with > or = 3 mm lumpectomy margins received PBI (40.5 Gy, 15 daily 2.7-Gy fractions) concurrently with the first two of four cycles of ddAC (60 and 600 mg/m2 of doxorubicin and cyclophosphamide, respectively, every 14 days with colony-stimulating support). Primary end points were local and systemic toxicity. Additional systemic therapy was given at the physician's discretion. RESULTS: Twenty-seven patients enrolled between November 2004 and January 2007, but two patients did not receive protocol therapy (one found with additional local disease and one withdrew consent). Twenty-five women completed all planned PBI. Four (16%) of 25 did not complete all ddAC ( febrile neutropenia [FN], n = 2; diverticulitis and neutropenia, n = 1; and social/economic reasons, n = 1). Four among the remaining 21 who completed all ddAC had a cycle delayed (FN, n = 1; acute respiratory illness, n = 1; foot blisters, n = 1; perianal dermatitis, n = 1). There was no grade 3 to 4 anemia or thrombocytopenia. Grade 3 nonhematologic toxicities (none grade 4) occurred in 28% (seven of 25) of patients ( nausea/ vomiting, n = 3; stomatitis, n = 2; contralateral breast abscess, n = 1; fatigue, n = 1; and cough/ bronchospasms, n = 1). The observed rate of > or = grade 2 skin toxicity was 0% (0 of 25; one-sided 95% CI, 0% to 11%). CONCLUSION: PBI with concurrent ddAC is feasible, and local/systemic toxicity is acceptable. Larger studies are warranted to assess long-term locoregional control and late toxicities.
|
Authors | Richard C Zellars, Vered Stearns, Deborah Frassica, Fariba Asrari, Theodore Tsangaris, Lee Myers, Shirley DiPasquale, Julie R Lange, Lisa K Jacobs, Leisha A Emens, Deborah K Armstrong, John H Fetting, Elizabeth Garrett-Mayer, Nancy E Davidson, Antonio C Wolff |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 27
Issue 17
Pg. 2816-22
(Jun 10 2009)
ISSN: 1527-7755 [Electronic] United States |
PMID | 19332718
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Doxorubicin
- Cyclophosphamide
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(diagnosis, drug therapy)
- Combined Modality Therapy
- Cyclophosphamide
(therapeutic use)
- Dose-Response Relationship, Drug
- Doxorubicin
(therapeutic use)
- Early Detection of Cancer
- Feasibility Studies
- Female
- Humans
- Radiotherapy, Adjuvant
- Treatment Outcome
|